Hypothesis: Systemic lupus erythematosus (SLE) flares are triggered when CD38 ectoenzyme upregulation on activated immune cells depletes intracellular NAD+ below a critical threshold (~50% of baseline), disabling SIRT1-mediated suppression of NF-kB and NLRP3 inflammasome activity. This same CD38-NAD+ depletion axis accelerates biological aging in SLE patients, explaining the 3-5 year epigenetic age acceleration observed in lupus cohorts.

Specific predictions:

1. Peripheral blood NAD+/NADH ratio will inversely correlate with SLEDAI-2K scores (r < -0.5) in a cross-sectional cohort (n>=80).
2. CD38+ monocyte frequency will predict flare onset 4-6 weeks before clinical manifestation (AUC > 0.80 in longitudinal sampling).
3. CD38 inhibitors (78c or apigenin) administered to MRL/lpr mice will simultaneously reduce anti-dsDNA titers and reverse epigenetic clock acceleration measured by Horvath multi-tissue clock adapted for murine CpG sites.

Proposed test: A 12-week observational cohort of 100 SLE patients with monthly NAD+ metabolomics (whole blood), CD38 flow cytometry, SLEDAI-2K, and epigenetic age (DNAm) at baseline and week 12. Primary endpoint: correlation between NAD+ nadir and flare incidence. Secondary: mediation analysis testing whether CD38 expression mediates the relationship between interferon gene signature and epigenetic age acceleration.

Why this matters for geroscience: If confirmed, this identifies a druggable metabolic node (CD38) where autoimmune pathology and biological aging converge — suggesting that NAD+ restoration strategies (NMN, NR, or CD38 inhibition) could simultaneously treat autoimmune flares and slow immunological aging.